BOLD-100
![]() BOLD-100 Chemical Structure | |
臨床資料 | |
---|---|
給藥途徑 | Intravenous |
識別資訊 | |
| |
CAS號 | 197723-00-5 |
PubChem CID | |
DrugBank | |
ChEBI | |
化學資訊 | |
3D模型(JSmol) | |
| |
|
BOLD-100,即反式四氯二(1H-吲唑)合釕(III)酸鈉,是一種臨床開發中的釕基的抗癌藥。截至2021年11月,在晚期胃腸道癌患者中,BOLD-100正與化療方案FOLFOX聯合進行1b期臨床試驗。[1]它由Bold治療有限公司開發。[2]
BOLD-100具有八面體結構,赤面上由兩個反式吲唑配體和四個氯離子配體,它的陽離子為鈉,且含有痕量的銫。[3]
參考文獻
- ^ U.S. National Library of Medicine. (2020). BOLD-100 in combination with FOLFOX for the treatment of advanced solid tumours. https://clinicaltrials.gov/ct2/show/NCT04421820 (頁面存檔備份,存於互聯網檔案館)
- ^ Bold Therapeutics. (2021). Technology. https://www.bold-therapeutics.com/technology (頁面存檔備份,存於互聯網檔案館)
- ^ Vojkovsky, T., Sill, K., Carie, A. (2018). Manufacture of trans-[tetrachlorobis(1H-inadazole)ruthenate(III)] and compositions thereof (U.S. Patent No. 10, 611,787). U.S. Patent and Trademark Office. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=2&f=G&l=50&d=PTXT&S1=10,611,787&OS=10,611,787&RS=10,611,787[失效連結])